{{Rsnum
|rsid=2032582
|Gene=ABCB1
|Chromosome=7
|position=87531302
|Orientation=minus
|ReferenceAllele=T
|MissenseAllele=G
|GMAF=0.3402
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=ABCB1
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 25.7 | 54.9 | 19.5
| HCB | 19.7 | 51.8 | 28.5
| JPT | 22.1 | 46.9 | 31.0
| YRI | 0.0 | 0.0 | 0.0
| ASW | 80.7 | 17.5 | 1.8
| CHB | 19.7 | 51.8 | 28.5
| CHD | 19.3 | 58.7 | 22.0
| GIH | 8.9 | 50.5 | 40.6
| LWK | 96.3 | 3.7 | 0.0
| MEX | 29.3 | 56.9 | 13.8
| MKK | 82.7 | 16.7 | 0.6
| TSI | 34.3 | 46.1 | 19.6
| HapMapRevision=28
}}
[[rs2032582]], also known as G2677T, is a nonsynonymous SNP located in exon 21 of the [[ABCB1]] gene. G2677 is also known as Ala893Thr. It is often studied in conjunction with [[rs1045642]].

The [[rs2032582]](T) variant allele yields a 2.6 fold higher risk of developing [[lung cancer]], and in particular, the type of lung cancer called squamous cell carcinoma (CI 1.7-4.0, P < .001). There appears to be little gene dosage effect, since homozygous [[rs2032582(T;T)]] carriers shoulder almost all the risk (odds ratio 6.75 compared to (A;A) homozygotes, CI 3.0-15.2). This risk is also independent of an individual's history of [[smoking]]. {{PMID|17120199}} 

A study of 98 methadone-maintaining patients concluded that the higher (>150 mg/day) and lower (< or =150 mg/day) [[methadone]] dose groups differed significantly in their [[rs1128503]] status (experiment-wise p = 0.0325). Furthermore, individuals with the 3-locus genotype pattern (T;T)-(T;T)-(T;T) for SNPs [[rs1045642]], [[rs2032582]] and [[rs1128503]], respectively, had an approximately 5-fold chance of requiring the 'higher' methadone dose, while individuals heterozygous for these three SNPs have an approximately 3-fold chance of stabilizing at the 'lower' methadone dose (point-wise p-value = 0.026).{{PMID|18424454|OA=1
}}

OMIM also reports an association with [[Crohn's disease]].

{{omim
| id = 171050
| quiet = 1
| variant = 0003
| desc    = CROHN DISEASE, SUSCEPTIBILITY TO
| rsnum   = 2032582
}}

{{ neighbor
| rsid = 2032583
| distance = 57
}}
{{ neighbor
| rsid = 4148739
| distance = 431
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1:2677G>T/A, mRNA 3095G>T/A, Ala893Ser/Thr
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:12914549
|Annotation=ABCB1 rs2032582 and rs1045642 genotype and peripheral blood lymphocyte efflux of P-gp substrate, rhodamine 123 (Rh123), in vitro, in healthy males: there was no significant difference in Rh123 efflux in CD56+ NK cells after 5, 10, 15, and 30 min efflux, or in CD4+ T-helper cells after 15, 30, 60, and 90 min between individuals with different genotypes. Rh123 efflux was not enhanced by a 10-day administration of P-gp inducer, rifampin, in vivo in 15 individuals before and after rifampin treatment. No genotypic effect was observed for inhibition of Rh123 efflux by P-pg inhibitor, verapamil, in vitro with CD56+ and CD4+.
|Drugs=rhodamine 123; rifampin; verapamil
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110727
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1:2677G>A/T
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/abcb1/variant.jsp#ImportantVariantInformationforABCB1-2677
|Annotation=This SNP is well-studied but there is no clear consensus on its significance for drug disposition, response or toxicity.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161145210
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=MDR1 G2677T/A, MDR1 (2677G, 893 Ala), MDR1 (2677T, 893 Ser), MDR1 (2677A, 893 Thr)
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:18408561
|Annotation=In multiple myeloma patients treated with dexamethasone, doxorubicin, and vincristine, followed by autologous stem cell transformation (ASCT), treatment efficacy was not related to this variant. However, the overall survival of patients with the G/G genotype of this variant was significantly lower than that of patients carrying T/T or G/T alleles. In ASCT nonresponders, diplotype analysis of this variant together with another variant (ABCB1 C3435T) showed that GC/GC patients survived for less time than GC/TT and TT/TT patients.
|Drugs=dexamethasone; doxorubicin; vincristine
|Drug Classes=
|Diseases=Multiple Myeloma
|Curation Level=Curated
|PharmGKB Accession ID=PA161659509
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:17913323
|Annotation=This study suggests a possible association of ABCB1 variants with SSRIs response. In a Japanese major depression sample this non-synonymous SNP showed significant association with treatment response to paroxetine.
|Drugs=paroxetine
|Drug Classes=
|Diseases=Depression
|Curation Level=Curated
|PharmGKB Accession ID=PA162191302
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1: G2677T/A; Ala893Ser/Thr
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19143748
|Annotation=A study of 83 patients found that patients heterozygous for this variant in ABCB1 had a significantly higher clearance of paclitaxel than most other ABCB1 variants.
|Drugs=paclitaxel
|Drug Classes=
|Diseases=Ovarian Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA162411187
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1: 2677G>T/A
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:16467099
|Annotation=This variant have been associated with response to palitaxel.
|Drugs=paclitaxel
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA164920324
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1: 2677G>T/A
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:16950614
|Annotation=Patients with both rs1045642 and rs2032582 variants have been associated with neutropenia from paclitaxel.
|Drugs=paclitaxel
|Drug Classes=
|Diseases=Neutropenia
|Curation Level=Curated
|PharmGKB Accession ID=PA164920326
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1: 2677G>T/A
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19203783
|Annotation=Patients with epithelial ovarian cancer, with this variant, have been associated with response to taxane- and platinum-based therapy and gastrointestinal toxicity.
|Drugs=carboplatin; cisplatin; docetaxel; paclitaxel
|Drug Classes=TAXANES
|Diseases=Ovarian Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA164920325
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1: 2677T/A>G
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19450124
|Annotation=This variant maybe associated with drug resistance in chinese epilepsy patients. Sample size: 464 chinese epilepsy patients (270 drug responsive, 194 drug resistant).
|Drugs=carbamazepine; clobazam; clonazepam; gabapentin; lamotrigine; levetiracetam; phenobarbital; phenytoin; topiramate; valproic acid; vigabatrin
|Drug Classes=
|Diseases=Epilepsy
|Curation Level=Curated
|PharmGKB Accession ID=PA164892191
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1:2677G>T/A, mRNA 3095G>T/A, Ala893Ser/Thr
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:18717915
|Annotation=peak blood concentration of cyclosporin A (CsA) was significantly lower in in myasthenia gravis patients harboring the 2677 T allele (893Ser); and trough CsA levels were significantly greater in 2677 TT homozygotes versus CC homozygotes
|Drugs=cyclosporine
|Drug Classes=
|Diseases=Myasthenia Gravis
|Curation Level=Curated
|PharmGKB Accession ID=PA164944055
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1:2677G>T/A, mRNA 3095G>T/A,  p.Ala893Ser/Thr
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:16331627
|Annotation=Clinical outcome and P-gp activity was studied in Asian patients with de novo acute myeloid leukemia taking cytarabine and idarubicin, relative to ABCB1 genotypes, C3435T (rs1045642) and G2677T/A (rs2032582, Ala893Ser/Thr). Three-year event-free survival (EFS) was higher in 2677 GG homozygotes (893Ala/Ala) (60.6%) versus non-GG genotypes (893Ser allele-harboring subjects) (21.9%; p = 0.02), and in 3435 CC homozygotes versus non-CC genotypes (p = 0.01), and for 2677GG (893Ala/Ala)/3435CC diplotypes (58.2%) versus other diplotypes (22.6%; p = 0.04); although no significant genotypic or haplotypic association was observed for overall survival (OS). The rate of complete remission was significantly higher in 3435 CC (p = 0.05) and 2677 GG (893Ala/Ala) (p = 0.04) homozygotes, and for the 3435CC/2677GG diplotype (p = 0.03) compared to non-GC haplotype homozygotes. Using an in vitro daunorubicin accumulation assay with leukemic mononuclear cells from AML patients, 3435 CC homozygotes showed significantly lower P-gp activity (7.5%) than for CT (10.7%) and TT (19.9%) genotypes (p = 0.029); and G2677T/A (Ala893Ser/Thr) genotype had no effect (p = 0.181).
|Drugs=cytarabine; idarubicin
|Drug Classes=
|Diseases=Leukemia, Myeloid, Acute
|Curation Level=Curated
|PharmGKB Accession ID=PA164953198
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1:2677G>T/A, mRNA 3095G>T/A, Ala893Ser/Thr
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:11503014
|Annotation=893Ser-expressing (ABCB1:2677G>T (Ala893Ser)) cells showed 47% lower intracellular digoxin concentration (p < 0.002) than Ala893-expressing cells; and 893Ser/Ser homozygotes showed statistically different fenofexadine area under the concentration curve (AUC) values for 0-4 hours (p = 0.054) than 893Ala/Ala homozygotes.
|Drugs=digoxin; fexofenadine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA164944053
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1:2677G>T/A, mRNA 3095G>T/A, Ala893Ser/Thr
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:17206635
|Annotation=There is a significant association between the G2677T/A polymorphism distribution and the risk for cyclosporin A (CsA) failure in patients from France and Belgium with steroid resistance ulcerative colitis (p = 0.0001), defined as requiring colectomy within 30 days of CsA initiation. The 2677 TT genotype was significantly associated with the risk compared with the two other genotypes (odds ratio, 3.77; 95% confidence interval, 1.42-9.97, p = 0.007).
|Drugs=cyclosporine
|Drug Classes=
|Diseases=Colitis, Ulcerative
|Curation Level=Curated
|PharmGKB Accession ID=PA164953178
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1:2677G>A/T
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:18377430
|Annotation=Risk or phenotype-associated allele: T. Phenotype: A haplotype of ABCB1 c.1236C>T, c.2677G>A/T, and c.3435C>T (rs1128503, rs2032582 and rs1045642) was associated with increased drug exposure and reduced clearance. Study size: . Study population/ethnicity: Asian patients with Breast Neoplasms treated with doxorubicin. Significance metric(s): p = 0.03 (exposure); p= 0.01 (clearance). Type of association: PK.
|Drugs=doxorubicin
|Drug Classes=
|Diseases=Breast Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165291810
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1: c.2677G>T/A, mRNA 3095G>T/A, p.Ala893Ser/Thr
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:12781336
|Annotation=Functional study of rs1045642 (3435C>T) and rs1128503 (2677G>T/A): in LLC-PK1 cells expressing wild-type (2677G/3435C) or polymorphic (2677G/3435T, 2677A/3435C, 2677A/3435T, 2677T/3435C, 2677T/3435T) constructs of ABCB1 in vitro, no significant differences were observed in transcellular efflux of structurally diverse P-gp substrates, verapamil, digoxin, vinblastine or cyclosporin A.
|Drugs=cyclosporine; digoxin; verapamil; vinblastine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110267
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1: c.2677G>T/A, mRNA 3095G>T/A, p.Ala893Ser/Thr
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:12781336
|Annotation=Functional study of rs1045642 (3435C>T) and rs2032582 (2677G>T/A): in LLC-PK1 cells expressing wild-type (2677G/3435C) or polymorphic (2677G/3435T, 2677A/3435C, 2677A/3435T, 2677T/3435C, 2677T/3435T) constructs of ABCB1 in vitro, no significant differences were observed in transcellular efflux of structurally diverse P-gp substrates, verapamil, digoxin, vinblastine or cyclosporin A.
|Drugs=cyclosporine; digoxin; verapamil; vinblastine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110367
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1: c.2677G>T/A, mRNA 3095G>T/A, p.Ala893Ser/Thr
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:15521904
|Annotation=Haplotypes derived from the SNPs 2677G > T (rs2032582) and 3435C > T (rs1045642) do not influence the pharmacokinetics of tacrolimus in renal transplant patients
|Drugs=tacrolimus
|Drug Classes=
|Diseases=Transplantation
|Curation Level=Curated
|PharmGKB Accession ID=PA165110371
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1: c.2677G>T/A, mRNA 3095G>T/A, p.Ala893Ser/Thr
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:14600574
|Annotation=No significant association between allelic ABCB1 variants, C3435T (rs1045642) and G2677T/A (Ala893Ser) (rs2032582), and phase 1 or phase 2 viral decay, changes in lymphocyte subsets over time, or plasma trough ritonavir concentrations among 31 HIV-infected individuals initiating antiretroviral therapy.
|Drugs=ritonavir
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110369
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1:2677G>T/A, 3095G>T/A, Ala893Ser/Thr
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:18851956
|Annotation=Risk or phenotype-associated allele: 2677 T (893Ser) and A (893Thr) alleles. Phenotype: Carriers of 3435 CT and TT genotypes (63%) and 2677 non-GG (non 893Ala/Ala) genotypes (64%) had higher frequency of family history of coronary artery disease (CAD) than the 3435CC (44%, p = 0.042) and 2677GG (46%, p = 0.043) carriers. The frequency of CAD in those carrying the 3435/2677 T/T haplotype (67%) was higher than that found in 3435/2677 non-T/T individuals (47%, p = 0.021). Reduction in ABCB1 expression in peripheral blood mononuclear cells was associated with 2677 T and A alleles (p = 0.039). ABCC1 mRNA expression was reduced 50% in response to atorvastatin (p < 0.05), and correlated with 2677 T (893Ser) allele carriers versus 2677 GG (893Ala/Ala) homozygotes (p = 0.04). Increased response to atorvastatin was found in 2677A allele carriers (OR = 5.69, 95% CI = 1.28-25.24, p = 0.022). ABCB1 substrates (antiarrhythmics, beta-blockers, diuretics, ACE inhibitors, and others) or inhibitors (antiarrhythmics, calcium antagonists, calcium channel blockers, antidepressants and others) did not affect the baseline ABCB1 expression, but ABCB1 inhibitors reversed the effects of atorvastatin on both ABCB1 and ABCC1 transporters. Study size: 136. Study population/ethnicity: Hypercholesterolemic individuals, treated with atorvastatin (10mg/day/4 weeks), evaluated for CAD risk factors at the Institute Dante Pazzanese of Cardiology and the Hospital of the Sao Paulo University in Sao Paulo City, Brazil. Significance metric(s): p < 0.05. Type of association: GN; PD; FA
|Drugs=atorvastatin
|Drug Classes=
|Diseases=Coronary Artery Disease; Hypercholesterolemia
|Curation Level=Curated
|PharmGKB Accession ID=PA165110750
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1: c.2677G>T/A, mRNA 3095G>T/A, p.Ala893Ser/Thr; ABCB1*7
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:15122075
|Annotation=Risk or phenotype-associated allele: none. Phenotype: There was no significant association between systemic exposure of tipifarnib (AUC levels) and rs2032582 genotype. Study size: 28 (16 male). Study population/ethnicity: Caucasian cancer patients, aged 34-75. Significance metric(s): Not significant, p = 0.92. Type of association: GN; PK
|Drugs=Tipifarnib
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165111312
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1: A893S
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19940846
|Annotation=Increased intracellular BODIPy-FL- paclitaxel levels (decreased function) in transfected cells
|Drugs=paclitaxel
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA165111606
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1:A893T
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19940846
|Annotation=Decreased intracellular calcein levels (increased function) in transfected cells
|Drugs=calcein
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA165111605
}}

{{PharmGKB
|RSID=rs2032582
|Name_s=ABCB1: c.2677G>T/A, mRNA 3095G>T/A, p.Ala893Ser/Thr
|Gene_s=ABCB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:12065748
|Annotation=Drug efflux and cell surface expression (by MRK-16 and C219 probes) of P-gp was not different between wild-type and variant forms (single mutants: N21D, F103L, S400N, A893S, A998T, and double mutants: 21D-S400N, N21D-A893S, and S400N-A893S) in an in vitro vaccinia virus-based transient expression system. Fluroescent substrates included calcein AM, bodipy-FL-forskolin, bodipy-FL-verapamil, bodipy-FL-vinblastine, bodipy-FL-prazosin, bisantrene, and bodipy-FL-paclitaxel. There was a slight increase in wild-type P-gp efflux of bodipy-FL-paclitaxel over mutants.
|Drugs=bisantrene; calcein; forskolin; prazosin; verapamil; vinblastine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110363
}}
{{PMID Auto
|PMID=20944127
|Title=Two multidrug-resistance (ABCB1) gene polymorphisms as prognostic parameters in women with ovarian cancer
}}
{{PMID Auto
|PMID=21287651
|Title=Different Transport Activity of Human Triallelic MDR1 893Ala/Ser/Thr Variant and its Association with Herb Extracts
}}

{{omim
|id=610064
|rsnum=2032582
}}

{{PMID Auto
|PMID=21902503
|Title=ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia
}}

{{PMID Auto
|PMID=22015057
|Title=Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
}}

{{PMID Auto
|PMID=22110582
|Title=Association of MDR1 Gene SNPs and Haplotypes with the Tacrolimus Dose Requirements in Han Chinese Liver Transplant Recipients
|OA=1
}}

{{PMID Auto
|PMID=22120734
|Title=Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia
}}

{{PMID Auto
|PMID=21705081
|Title=Multidrug resistance gene expression and ABCB1 SNPs in plasma cell myeloma
}}

{{PMID Auto
|PMID=22176633
|Title=ABCB1/MDR1 polymorphism and colorectal cancer risk: a meta-analysis of case-control studies
}}

{{PMID Auto
|PMID=21806386
|Title=Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients
}}

{{PMID Auto
|PMID=15197162
|Title=Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene.
|OA=1
}}

{{PMID Auto
|PMID=16103896
|Title=An association study of 43 SNPs in 16 candidate genes with atorvastatin response.
}}

{{PMID Auto
|PMID=16999857
|Title=ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients.
|OA=1
}}

{{PMID Auto
|PMID=17146660
|Title=Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers.
}}

{{PMID Auto
|PMID=17548681
|Title=MDR1 gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia.
}}

{{PMID Auto
|PMID=17674045
|Title=No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients.
}}

{{PMID Auto
|PMID=18213362
|Title=Multiplexed genotyping of ABC transporter polymorphisms with the Bioplex suspension array.
|OA=1
}}

{{PMID Auto
|PMID=18442890
|Title=Association of a polymorphism of ABCB1 with obesity in Japanese individuals.
}}

{{PMID Auto
|PMID=18518969
|Title=Association of ABCB1 genetic variants with renal function in Africans and in Caucasians.
|OA=1
}}

{{PMID Auto
|PMID=18698231
|Title=Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues.
|OA=1
}}

{{PMID Auto
|PMID=18725235
|Title=Bidirectional translational research: Progress in understanding addictive diseases.
|OA=1
}}

{{PMID Auto
|PMID=18784455
|Title=The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.
|OA=1
}}

{{PMID Auto
|PMID=18812236
|Title=No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population.
}}

{{PMID Auto
|PMID=18854777
|Title=Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy.
|OA=1
}}

{{PMID Auto
|PMID=19155191
|Title=Opiate and cocaine addiction: from bench to clinic and back to the bench.
|OA=1
}}

{{PMID Auto
|PMID=19667110
|Title=Identification of genetic variants associated with response to statin therapy.
}}

{{PMID Auto
|PMID=19694740
|Title=No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
|OA=1
}}

{{PMID Auto
|PMID=19740399
|Title=Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant.
|OA=1
}}

{{PMID Auto
|PMID=20170205
|Title=Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
}}

{{PMID Auto
|PMID=20214406
|Title=Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
}}

{{PMID Auto
|PMID=20354687
|Title=Explaining variability in ciclosporin exposure in adult kidney transplant recipients.
|OA=1
}}

{{PMID Auto
|PMID=20389299
|Title=Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.
|OA=1
}}

{{PMID Auto
|PMID=20533057
|Title=ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer.
|OA=1
}}

{{PMID Auto
|PMID=21102498
|Title=Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients.
}}

{{PMID Auto
|PMID=21172166
|Title=Pharmacogenetics of antidepressant response.
|OA=1
}}

{{PMID Auto
|PMID=21185600
|Title=Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.
}}

{{PMID Auto
|PMID=21468756
|Title=The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
}}

{{PMID Auto
|PMID=21544031
|Title=Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity.
}}

{{PMID Auto
|PMID=21553324
|Title=Polymorphisms of the MDR1 and MIF genes in children with nephrotic syndrome.
}}

{{PMID Auto
|PMID=21827404
|Title=The clinical impact of ABCB1 polymorphisms on the treatment of psychiatric diseases.
}}

{{PMID Auto
|PMID=21840870
|Title=Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
}}

{{PMID Auto
|PMID=21896346
|Title=Polymorphisms in genes that regulate cyclosporine metabolism affect cyclosporine blood levels and clinical outcomes in patients who receive allogeneic hematopoietic stem cell transplantation.
}}

{{PMID Auto
|PMID=22112610
|Title=Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
|OA=1
}}

{{PMID Auto
|PMID=22134106
|Title=ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib.
}}

{{PMID Auto
|PMID=22136368
|Title=Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians.
}}

{{PMID Auto
|PMID=22306099
|Title=Association between the functional polymorphism (C3435T) of the gene encoding P-glycoprotein (ABCB1) and major depressive disorder in the Japanese population.
}}

{{GET Evidence
|gene=ABCB1
|aa_change=Ser893Thr
|aa_change_short=S893T
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2032582
|overall_frequency_n=6
|overall_frequency_d=128
|overall_frequency=0.046875
|n_genomes=4
|n_genomes_annotated=0
|n_haplomes=4
|n_articles=0
|n_articles_annotated=0
|nblosum100=-2
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=22672924
|Title=Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas
}}

{{PMID Auto
|PMID=23188198
|Title=ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
|OA=1
}}

{{PMID Auto
|PMID=23279665
|Title=ABCB1/MDR1 gene polymorphism and colorectal cancer risk: a meta-analysis of case-control studies
}}

{{PMID Auto
|PMID=23546964
|Title=Frequency of MDR1 single nucleotide polymorphisms in a Jordanian population, including a novel variant
}}

{{PMID Auto
|PMID=23093106
|Title=Detection of frequent ABCB1 polymorphisms by high-resolution melting curve analysis and their effect on breast carcinoma prognosis
}}

{{PMID Auto
|PMID=23556446
|Title=Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease
}}

{{PMID Auto
|PMID=23372834
|Title=ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohort
|OA=1
}}

{{PMID Auto
|PMID=23917080
|Title=ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas
}}

{{PMID Auto
|PMID=24469730
|Title=Genetic association of the P-glycoprotein gene ABCB1 polymorphisms with the risk for steroid-induced osteonecrosis of the femoral head in Chinese population
}}

{{PMID Auto
|PMID=23133420
|Title=Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin.
|OA=1
}}

{{PMID Auto
|PMID=23133441
|Title=ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients.
|OA=1
}}

{{PMID Auto
|PMID=23443032
|Title=Fetal polymorphisms at the ABCB1-transporter gene locus are associated with susceptibility to non-syndromic oral cleft malformations.
}}

{{PMID Auto
|PMID=23733030
|Title=Pharmacogenetics in major depression: a comprehensive meta-analysis.
}}

{{PMID Auto
|PMID=24918524
|Title=Association study between the MDR1 gene and clinical characteristics in schizophrenia
}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}